Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Trends in Molecular Medicine|October 30, 2024
Immune-mediated colitis after immune checkpoint inhibitor therapySophie Giesler, Roxane Riemer, Theresa Lowinus, et al.
Oncotarget|July 28, 2016
Immunomodulation by memantine in therapy of Alzheimer's disease is mediated through inhibition of Kv1.3 channels and T cell responsivenessTheresa Lowinus, Tanima Bose, Stefan Busse, et al.
European Journal of Immunology|August 30, 2012
Constitutive Akt1 signals attenuate B-cell receptor signaling and proliferation, but enhance B-cell migration and effector functionMandy Pierau, Shin-Young Na, Narasimhulu Simma, et al.
Molecular and Cellular Biology|December 18, 2013
Immunosuppression by N-methyl-D-aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 channels in T cellsSascha Kahlfuß, Narasimhulu Simma, Judith Mankiewicz, et al.
Cell Communication and Signaling : CCS|December 6, 2014
NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cellsNarasimhulu Simma, Tanima Bose, Sascha Kahlfuss, et al.
Cell Communication and Signaling : CCS|January 18, 2019
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signalingTheresa Lowinus, Florian H Heidel, Tanima Bose, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 10, 2023
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cellsClemens Cammann, Jonas Kulla, Lüder Wiebusch, et al.
Pathologie (Heidelberg, Germany)|June 27, 2025
[Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board]Elaine-Pashupati Dopfer, Matthias Fahrner, Johanna Thiery, et al.
International Journal of Cancer|May 16, 2026
Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in GermanyGlenn Geidel, Theresa Lowinus, Patrick Metzger, et al.
British Journal of Haematology|August 4, 2023
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with responsePetya Apostolova, Stefanie Kreutmair, Cristina Toffalori, et al.
Pageof 2